A peer support community, independent and not for sale. Since February 2024.

GLP CircleA peer support community

Peptides beyond GLP-1

Semaglutide and cagrilintide in combination — what is published

Started 27 January 2026 · 13 replies · 108 hearts · read 1.6k times

FlossieShrewsbury, UK · 27 January 2026
6 months ago

Semaglutide and cagrilintide in combination — what is published — putting it in its own thread so it does not get lost in the check-in.

I have read the paper and I am not sure I have understood it.

Evidence question. I would rather have an honest "we do not know" than a confident answer, and confident answers are all I have been able to find so far.

I would like to compare how two different measurements answer two different questions, because I have been treating them as interchangeable.

No hurry on this one. It is a reading question rather than a decision.

36

BunnyWeston-super-Mare, UK
#1

The dosing discussion in most places online is derived from animal work by arithmetic, and that arithmetic does not do what people think it does.

8me too 7

MableBolton, UK
#2

Flossie, I have been where you are and I would rather say so than stay quiet.

Nothing here is a recommendation. This circle exists to be honest about where the evidence runs out, not to fill the gap with confidence.

7

SunilFacilitatorBirmingham, UK
#3

A standing request in this circle: when you bring a paper, say what the methods section actually did. It is the part everybody skips and the part that decides what the paper is worth.

12

TamarPlymouth, UK
#4

My approach now is to ask what would have to be true for a claim to hold, and then to look for whether anybody has checked.

11

AbramAmsterdam, NL
#5

Picking up Sunil’s point rather than starting a new one.

What I would flag is that the safety data is the part that is thinnest, and it is the part that matters most.

8

PolaGdańsk, PL
#6

Nothing in this circle is medical advice and none of us is in a position to tell you what is safe for you.

4

IdrisCardiff, UK
#7

My honest experience is that the more I read here, the more conservative I have become about the whole category.

10

FabianBasel, CH
#8

Pola has already said most of this and I want to add the one part that was different for me.

Something that helped was somebody here distinguishing between compounds with a real clinical programme and compounds without one.

3

TacitaRome, IT
#9

Quietly agreeing from the other side of the country.

7

NevGrimsby, UK
#10

The reading group format works well for this. We took one compound, found everything published, and concluded it was thinner than the discussion suggested.

8

TobinCork, IE
#11

Gently disagreeing with Nev, or rather adding the other half of it.

Something worth knowing: a compound being widely discussed tells you about the discussion rather than about the compound.

7

SunilFacilitatorBirmingham, UK
#12

Speaking as a facilitator: we do not name individuals in this circle and we do not accuse anybody of anything. We describe what a document does and does not show.

18

MorayElgin, UK
#13

I found that separating the mechanism claims from the outcome claims made the whole subject much easier to think about.

5me too 1